Fluoroscopy guided percutaneous biopsy in combination with bronchoscopy and endobronchial ultrasound in the diagnosis of suspicious lung lesions – the triple approach

Abstract

Flexible bronchoscopy and endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) are the pulmonologists´basic procedures for the biopsy of suspicious lung lesions. If inconclusive, other guiding-modalities for tissue sampling are needed, computed tomography performed by a radiologist, orif availableradial EBUS or electromagnetic navigation biopsy.We wanted to investigate if same-day X-ray fluoroscopy-guided transthoracic fine-needle aspiration biopsy (F-TTNAB) performed by the pulmonologist immediately after bronchoscopy and EBUS is a feasible alternative.We retrospectively identified consecutive patients in whom F-TTNAB followed a bronchoscopy and EBUS in the same séance. Patients in whom the suspicion of malignancy was invalidated after complete work up were followed for six months to identify false-negative cases.In total 125 patients underwent triple approach (bronchoscopy, EBUS and F-TTNAB) during the same séance. Malignancy was diagnosed in 86 (69%), and 77 of these (90%) were primary lung cancers. The diagnostic yield of F-TTNAB for malignancy was 77%, and sensitivity was 90%. Pneumothorax occurred in 35 (28%) patients, and was administered with pleural drainage in 22 (18% of all patients). No cases of prolonged haemoptysis were observed. The risk of pneumothorax differed insignificantly with lesion size ≤2.0 cm (27%) versus >2.0 cm (29%).We conclude that it is feasible for pulmonologist to perform F-TTNAB immediately after endoscopy as a combined triple approach in a fast-track workup of suspected lung cancer.

Breaking potentially bad news of cancer workup to well‐informed patients by telephone versus in‐person: A randomised controlled trial on psychosocial consequences

“…(Silvestri et al, 2013; Lung Cancer Package Pathways in Denmark (Danish), 2018) Our unit offers single‐day invasive workup with bronchoscopy, endosonography and percutaneous biopsies. (Madsen et al, 2016; Sidhu et al, 2020).…”

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression

“…Transthoracic sampling from lung lesions is performed guided by Ultra Sound (US), fluoroscopy or CT, and percutaneous non-lung lesions (e.g. peripheral lymph nodes, liver, spleen, skin) are reached by US-guided biopsy [5][6][7][8]. Whenever possible, histological biopsies were obtained (e.g.…”